11 November 2023 in Journal of Colloid and Interface Science
3 September 2025 in Journal of Alzheimer’s Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and the accumulation of amyloid-β plaques and tau tangles in the brain. Current treatments are predominantly symptomatic and do not alter the underlying pathological processes, which include amyloid aggregation, tau hyperphosphorylation, synaptic dysfunction, and neuroinflammation. Nanoparticle-based drug delivery systems have emerged as a promising strategy to address these challenges by facilitating the targeted delivery of therapeutics across the blood-brain barrier, enhancing drug bioavailability, and minimizing systemic toxicity and immunogenicity through biomimetic surface modifications, optimized physicochemical properties, and targeted delivery approaches. This review examines the multifaceted role of nanoparticles in AD therapy under various pathological mechanisms. Additionally, the review explores the diagnostic potential of nanoparticles in improving the detection of AD biomarkers, offering early diagnosis and real-time monitoring of disease progression. Despite these promising developments, the clinical translation of nanoparticle-based approaches faces challenges related to biocompatibility, long-term safety, and regulatory barriers. Ongoing research and innovation are essential to optimize nanoparticle formulations, ensure their safety, and bring these advanced technologies into clinical practice. Nanotechnology represents a paradigm shift in AD management, offering the potential for more effective treatments and improved patient outcomes.
1 January 2026 in Bioactive Materials
Inducing immunogenic cell death (ICD) in cancer cells provides a promising approach in immunotherapy, however, oxidative stress relief and metabolic plasticity enhancement limit the immune-stimulating effect of traditional ICD inducer in sentinel lymph nodes (SLN), owing to the metabolism of fatty acids. In this article, a biocompatible green liposome CL-Lip was designed to not only selectively induce ICD in primary and metastatic 4T1 cells, but also relieved the immunosuppression in invasive SLN. CL-Lip is composed of engineered liposomes modified with linoleic acid and catalase, which synergistically trigger ICD, stimulate lipid peroxidation, PD-L1 carbonylation and effectively promote the maturation of dendritic cells and T cell differentiation. Moreover, catalase also downregulated the hypoxia level in SLN. Through cellular experiments and transcriptome analysis, it is proved that the ICD induction via CL-Lip is mediated by ROS generation, resulting from the YAP-dependent fatty acid oxidation (FAO) interference. Transcriptome analysis revealed that engineered CL-Lip diminishes YAP-dependent FAO pathway and effectively antagonizes the metabolic flexibility, thereby selectively triggering the metabolic dead-associated ICD process in both primary and metastatic 4T1 cells. In animal experiments, this little reported metabolic-driven ICD route not only significantly reduces metastatic foci, but also induces a “cold-to-hot” remodeling of SLN, resulting in the formation of a in situ tumor vaccine. These findings hold great significance for the development of next-generation ICD inducers and immunotherapy approaches.